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Sarcoidosis is an idiopathic multisystem disease characterized by the formation of noncaseating granulomas. It frequently presents
with pulmonary infiltrates and bilateral hilar and mediastinal lymphadenopathy. Splenic involvement is common, but massive
splenomegaly is a rare occurrence. Sarcoidosis is known as “the great mimicker” (or “the great imitator”) since it exhibits a
myriad of symptoms, mimicking other inflammatory, infectious, and neoplastic conditions, including lymphoma. Herein, we
report the case of a 44-year-old male patient who was found to have bicytopenia, hypercalcemia, diffuse lymphadenopathy, and
massive splenomegaly, a constellation of findings suggestive of underlying lymphoma. Interestingly, lymph node biopsy showed
noncaseating granulomas suggestive of sarcoidosis, without evidence of malignancy.

1. Introduction
Sarcoidosis is a chronic inflammatory disorder of unknown
origin which occurs mainly in young people [1, 2]. It is
characterized by the presence of noncaseating granulomas.
Although the lung is the most common organ involved,
the disease can affect any organ, including the spleen [1].
Granulomatous infiltration of the spleen is common in
sarcoidosis and is often asymptomatic [2]. Splenomegaly is
unusual, and massive splenomegaly is very rare [3].
The symptoms of sarcoidosis, if present, are nonspecific.
The presence of noncaseating granulomas is also not pathognomonic of the disease, as it can be seen in malignancy
[1]. Moreover, the involvement of the reticuloendothelial
system in sarcoidosis, as evidenced by enlarged lymph nodes
and splenomegaly, often mandates tissue examination to
exclude an underlying masked lymphoma. Sarcoidosis is well
known to be “the great mimicker” (or “the great imitator”),
since it exhibits a myriad of symptoms, mimicking other
inflammatory, infectious, and neoplastic conditions, including lymphoma.

Herein, we report the case of a 44-year-old male patient
who was found to have bicytopenia, hypercalcemia, diffuse
lymphadenopathy, and massive splenomegaly, a constellation
of findings suggestive of underlying lymphoma. Surprisingly,
lymph node biopsy showed noncaseating granulomas suggestive of sarcoidosis, without evidence of malignancy.

2. Case Presentation
We report the case of a 44-year-old Caucasian male who was
referred to our hospital by his primary physician for abnormal outpatient laboratory test values. The patient had been
healthy until 5 months prior to admission, when he started to
have progressively worsening fatigue. Outpatient blood tests
revealed kidney injury, hypercalcemia, and anemia, findings
that required hospitalization.
On the day of admission, the patient’s only complaint was
severe fatigue. Upon further questioning, he admitted having
a 70-pound unintentional weight loss over the last 18 months.
He denied any fever, chills, night sweats, cough, rash, or joint
or abdominal pain. His prior medical history consisted of

2

Case Reports in Medicine

(a)

(b)

Figure 1: Massive splenomegaly. (a) Sagittal sonographic view of the spleen showing a markedly enlarged and diffuse heterogeneous spleen
(blue arrow) measuring 30 cm in length. (b) Coronal noncontrast CT of the abdomen and pelvis showing enlarged spleen reaching 33.6 cm
in length.

(a)

(b)

Figure 2: Diffuse lymphadenopathy. (a) Transverse CT of the abdomen showing enlarged para-aortic lymph nodes (blue arrows) reaching
14 mm in the shortest axis. (b) Transverse CT of the pelvis showing enlarged inguinal lymph nodes reaching 15 mm in the shortest axis.

diabetes mellitus, gout, and hyperlipidemia. The patient was
a nonsmoker and had no allergies. His family history was
noncontributory.
On physical exam, the patient’s body temperature was
98.6∘ F, blood pressure was 159/92 mmHg, and heart rate
was 100/min. Cardiovascular and pulmonary exams were
unremarkable. Left upper quadrant tenderness was noted on
the abdominal exam, as well as a firm and enlarged spleen,
which was palpable below the umbilicus. No rash, cervical,
or axillary lymphadenopathy was identified.
Laboratory analysis showed a normocytic anemia with
a hemoglobin of 6.7 g/dL, a hematocrit of 21.4%, and a
mean corpuscular volume (MCV) of 82.3 𝜇m3 . The rest
of the hematologic panel was as follows: white blood cell
count of 3.93 × 109 /L, platelet count of 254 × 109 /L, and
erythrocyte sedimentation rate (ESR) of 93 mm/h. A peripheral blood smear was within normal limits. In addition,

hypercalcemia of 13.7 mg/dL was noted, along with a blood
urea nitrogen (BUN) of 33 mg/dL and a serum creatinine
of 2.39 mg/dL, findings consistent with kidney injury. The
renal function was normal three years ago. Liver enzymes
were normal. An abdominal sonogram showed a markedly
enlarged and diffusely heterogeneous spleen measuring
30 cm in length (Figure 1(a)). Enlarged kidneys with normal
echogenicity were found as well (right kidney 13 cm, left
kidney 15.5 cm). A noncontrast computed tomography (CT)
scan of the abdomen and pelvis confirmed the presence
of massive splenomegaly (Figure 1(b)), along with multiple
mildly enlarged paraaortic, mesenteric, and bilateral iliac
chain lymph nodes (Figure 2). A chest radiograph was unremarkable; however, a CT chest revealed diffuse mediastinal,
lower cervical, and axillary adenopathy.
The patient received packed red blood cells transfusions
to maintain his hemoglobin level around 8 mg/dL. He was
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Figure 3: Nonnecrotizing granulomata. Low- (a) and high-magnification (b) photomicrograph of a section from an inguinal lymph node. It
shows that the lymph node is replaced by numerous small compact nonnecrotizing granulomata.

also given intravenous fluids to treat the hypercalcemia and
received one dose of pamidronate, which helped to lower the
calcium level to as low as 11 mg/dL over the next few days.
The presence of massive splenomegaly and diffuse
lymph node enlargement was concerning lymphoma. Further
workup showed anemia of chronic disease and elevated
vitamin D 1,25(OH)2 levels (with low PTH levels). Antinuclear antibody, HIV test, monospot test, and purified
protein derivative (PPD) were negative. Additional studies
are listed in Table 1. A bone marrow biopsy revealed a
hypercellular marrow with negative cultures and cytogenetic
analysis. PCR analyses for Bcr/Abl and JAK2 mutation
were both negative. An excisional biopsy of a left inguinal
lymph node showed that the lymph node was extensively
involved with small compact nonnecrotizing granulomata
(Figure 3). Gomori methenamine silver (GMS) and acidfast bacillus (AFB) staining showed no fungal organisms or
acid-fast organisms, respectively. There was no morphologic
or immunophenotypic evidence of malignancy. Additional
serum studies showed an angiotensin-converting enzyme
(ACE) level of 73 U/L (reference range 9–67). These findings
led to a diagnosis of sarcoidosis, for which the patient was
started on prednisone 40 mg/day and discharged home few
days later.
Four weeks after the initiation of therapy, the patient’s
calcium level was 10.3 mg/dL, along with a hemoglobin
of 9.4 g/dL and a creatinine of 1.38 mg/dL. 2 weeks later,
ACE level was 31 mg/dL. 8 weeks after hospital discharge, a
fluorine-18 fluorodeoxyglucose (FDG) PET imaging, done
while the patient was still on treatment, showed no focal
FDG avid lesions, along with stable non-FDG avid thoracic
and abdominal adenopathy. The patient continued to be in
good health 9 months after his diagnosis and had shown no
progression of sarcoidosis.

3. Discussion
Sarcoidosis is a chronic idiopathic granulomatous disease
which can affect all age groups [1]. It has a slight predilection
for women in the third to fifth decades of life. Sarcoidosis
can affect virtually any organ system, with the lungs and
mediastinal lymphatic system being affected in up to 90%
of patients. In this setting, bilateral hilar adenopathy, with
or without interstitial lung disease, is a common finding.

Table 1: Laboratory findings.
Parameter
Total protein (g/dL)
Albumin (g/dL)
Serum iron (𝜇g/dL)
Total iron binding capacity (𝜇g/dL)
Ferritin (ng/mL)
Percent saturation (%)
Reticulocyte count (%)
ESR (mm/h)
Vitamin B12 (pg/mL)
Lactate dehydrogenase (IU/L)
Inorganic phosphorus (mg/dL)
Intact PTH (pg/mL)
PTH related protein (pg/mL)
Thyroid stimulating hormone (𝜇IU/mL)
Vitamin D 1,25(OH)2 total (pg/mL)
Vitamin D 25-OH total (ng/mL)
Uric acid (mg/dL)
Serum protein electrophoresis (SPEP)
Free kappa/lambda ratio
Urine protein electrophoresis (UPEP)

Value
8.1 (6–8.3)
3.2 (3.0–5.5)
34 (35–150)
241 (260–400)
608 (30–400)
14.1 (15–50)
1.88 (0.5–1.5)
93 (0–10)
215 (243–894)
97 (60–200)
2.5 (2.1–4.9)
5 (15–65)
22 (14–27)
2.72 (0.27–4.2)
248 (18–72)
26 (30–100)
6.3 (4.8–8.7)
Normal
1.01 (0.26–1.65)
Normal

Extrathoracic sarcoidosis is also common, with liver and
spleen involvement described in half of autopsy cases [2, 3].
Other commonly involved organs are the skin, the joints, and
the eyes.
Sarcoidosis can be asymptomatic in some patients. If
present, symptoms are both systemic (fever, weight loss, and
fatigue) and/or organ-specific (shortness of breath, chest
pain, and cough) [1]. There is no single laboratory test for
the diagnosis. However, cytopenia, eosinophilia, and hypergammaglobulinemia are common findings. Hypercalcemia
and/or hypercalciuria are also found in some cases. ACE,
produced by the epithelial cells of granulomas, is detected in
the serum of 60% of patients; however, its value in diagnosing
ormanaging sarcoidosis remains controversial [4]. Soluble
interleukin-2 receptor (sIL-2R) concentration, a marker of
T-cell activation, is considered to reflect disease activity. A
biopsy from the involved organ that is most easily accessed is
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recommended and is the only way to establish the diagnosis
[4, 5].
The diagnosis of sarcoidosis is based on criteria from the
American Thoracic Society (ATS), the European Respiratory
Society (ERS), and the World Association of Sarcoidosis and
Other Granulomatous Disorders (WASOG) [6]. These criteria include the following: the presence of clinicoradiological
findings suggestive of sarcoidosis, the presence of histological
evidence of noncaseating epithelioid cell granulomas, and
the exclusion of known causes of granulomatous reactions
[5, 6]. In fact, noncaseating granulomas are nonspecific for
sarcoidosis and are associated with some infections (such as
tuberculosis and histoplasmosis), occupational and environmental exposures (such as beryllium), autoimmune disorders
(such as Wegener’s granulomatosis), and malignancy (such as
lymphoma and solid tumors) [1].
Some patients with sarcoidosis are not disabled by the
illness and therefore do not require treatment [4]. In general,
treatment is initiated when impairment of organ function
is imminent. Oral prednisone at a dose of 20 to 40 mg
daily is the recommended regimen. In the case of adequate
response after 1 to 3 months, the prednisone dose should
be tapered to 5 to 15 mg daily, with treatment planned for
at least 6 additional months [4]. Sarcoidosis associated with
massive splenomegaly can be treated with either splenectomy
or corticosteroids, with no clear superiority of one modality
over the other [2, 7]. Splenectomy has not been shown
to alter the course of sarcoid progression. The indications
for splenectomy include intractable abdominal pain from
splenomegaly, functional asplenia, splenic rupture, hematologic abnormalities, massive splenomegaly refractory to
medical therapy, or a strong suspicion of an alternative
diagnosis [8].
Splenic involvement in sarcoidosis is defined as the
histologic presence of noncaseating granulomas in the spleen.
Autopsy studies show that the spleen is the second most
commonly affected organ in sarcoidosis, with the lung
being first [3]. Clinical evidence of splenomegaly is however
uncommon, present only in up to 27% of cases. Moreover, the
occurrence of massive splenomegaly in sarcoidosis is limited
to case reports. Although there is no consensus regarding the
definition of massive splenomegaly, most authors describe
it as when the spleen reaches the pelvis or has crossed
the midline into the right lower or right upper abdominal
quadrants. Other authors define it as when the spleen weights
more than 1000–1500 g or if the largest dimension is greater
than 20 cm (Poulin et al.). The most common etiologies of
massive splenomegaly include hematological disorders (such
as myeloproliferative disease and lymphomas), infectious
diseases (such as visceral leishmaniasis and malaria), and
infiltrative conditions (such as Gaucher disease) [9]. Massive
splenomegaly remains a rare manifestation of sarcoidosis.
In fact, in a large review by Fordice et al. of 6074 cases of
sarcoidosis, only 20 patients (3%) had massive splenomegaly
[10]. Differential diagnosis of massive splenomegaly is as
follows:
Myelofibrosis (primary or secondary).
Chronic myeloid leukemia.

Lymphoma (usually indolent).
Hairy cell leukemia.
Gaucher disease.
Amyloidosis.
Beta thalassemia major.
Schistosomiasis.
Kala-azar (visceral leishmaniasis).
Sarcoidosis (rarely).
Hyperreactive malarial splenomegaly syndrome
(tropical splenomegaly syndrome).
AIDS with mycobacterium avium complex.
Splenic vein thrombosis.
Splenic involvement in sarcoidosis is usually asymptomatic, although left upper quadrant pain is occasionally
present. Patients with splenomegaly may have a higher
incidence of constitutional symptoms and more disseminated
disease [11]. Splenic sarcoidosis may cause hypersplenism, as
evidenced by anemia, leukopenia, thrombocytopenia, or any
such combination. The radiographic features of splenic sarcoidosis are variable. Splenomegaly is usually homogeneous;
however, the sarcoid granulomas, often small, can coalesce
to produce macroscopically visible nodules. Therefore, in up
to 15% of patients, the disease may manifest as multiple lowattenuation and diffusely scattered nodules, ranging in size
from 1 to 30 mm [2, 12, 13]. This pattern may mimic other
worrisome diagnoses, such as lymphoma, metastases from
solid tumor, and tuberculosis [2, 3].
The crux of sarcoidosis is its ability to masquerade
as other diseases, most significantly lymphoma. As such,
for clinicians, distinguishing these entities can make the
difference between life and death for patients. In addition to
the nonspecific clinical, radiological, and histological features
in sarcoidosis, the lymphocyte activation and the reticuloendothelial system involvement (lymph nodes, spleen, and
liver) make the distinction of sarcoidosis from lymphoma
extremely challenging. In fact, hypercalcemia and increased
serum ACE levels have also been described in patients with
lymphoma [14]. Moreover, multiple reports confirmed the
presence of sarcoid-like (noncaseating epithelioid) granulomas in patients with lymphoma, even without a history of
“true” sarcoidosis [15]. Brincker concluded that a sarcoidlike granulomatous reaction occurred in 4% of cancers, in
14% of patients with Hodgkin’s lymphoma, and in 7% of
patients with non-Hodgkin’s lymphoma [15]. In our patient,
the combination of bicytopenia, hypercalcemia, diffuse lymphadenopathy, and massive splenomegaly favored a diagnosis
of lymphoma. Moreover, the patient had no clinical or
radiological evidence of respiratory system involvement to
suggest sarcoidosis as a “likely” diagnosis.
In some cases, the coexistence of “true” sarcoidosis
and lymphoproliferative disease has been reported in the
literature. In most of these cases, sarcoidosis preceded the
diagnosis of lymphoma, but in few other reports, lymphoproliferative disease occurred first [16]. This possible association
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between these two entities led to the so-called “sarcoidosislymphoma syndrome,” first suggested by Brincker in 1989
[17]. Since the diagnosis of sarcoidosis preceded the occurrence of the lymphoproliferative disease in most cases, he
suggested that sarcoidosis might be a paraneoplastic syndrome [17]. The causal relation between these two entities is
still a subject of speculation. It has been suggested that the
impairment of the immune system in sarcoidosis, in the form
of altered cell reaction and increased mitogenesis of B and T
lymphocytes, can predispose to the development of lymphoid
malignancies [18]. Moreover, the treatment of sarcoidosis
with steroids can further compromise the immune system
and may represent another predisposing factor for lymphoma
development [15].
FDG PET imaging remains an essential modality in the
management of lymphoma. One of many advantages it offers
over conventional imaging is the ability to detect occult
lesions. However, its specificity is limited by multiple falsepositive conditions, including infections, inflammations, and
sarcoidosis [19, 20]. In fact, in the setting of sarcoidosis, PET
imaging has been suggested to monitor disease progression
and response to therapy [21]. Since both sarcoidosis and
lymphoma are FDG avid, PET imaging cannot differentiate
these two conditions, and therefore histological verification
remains mandatory [20, 22].

4. Conclusion
This report illustrates an unusual case of sarcoidosis that presented as bicytopenia, hypercalcemia, diffuse lymphadenopathy, and massive splenomegaly, mimicking lymphoma. Physicians should be aware of this atypical presentation and
accordingly should consider sarcoidosis in their differential
diagnosis, after excluding other worrisome diagnoses, such
as lymphoma.
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